SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Anastrozole-d_{12}

Item No. 25360

CAS Registry No.:	120512-32-5
Formal Name:	α,α,α',α'-tetra(methyl-d_3)-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Synonym:	Anastrol-d_{12}
MF:	$C_{17}H_7D_{12}N_5$
FW:	305.4
Chemical Purity:	≥98% (Anastrozole)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_{12}); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Anastrozole-d_{12} is intended for use as an internal standard for the quantification of anastrozole (Item No. 11987) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Anastrozole-d_{12} is supplied as a solid. A stock solution may be made by dissolving the anastrozole-d_{12} in the solvent of choice. Anastrozole-d_{12} is soluble in the organic solvent chloroform, which should be purged with an inert gas.

Description

Anastrozole is an aromatase/CYP19A1 inhibitor (IC_{50} = 15 nM for human placental aromatase/CYP19A1).[1] It is selective for aromatase/CYP19A1 over the cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP3A (IC_{50}s = 27-650 µM). Anastrozole (0.1 mg/kg) blocks ovulation in mature female rats and androstenedione-stimulated uterine development in pubertal female rats.[2] It inhibits peripheral aromatase/CYP19A1 and reduces plasma estradiol concentrations in male pigtailed monkeys when administered at doses greater than 0.1 mg/kg. Anastrozole (0.5 mg/kg) reduces tumor incidence and the number of tumors by 40 and 57%, respectively, as well as increases latency to tumor appearance in a rat model of premenopausal mammary tumorigenesis.[3] Formulations containing anastrozole have been used in the treatment of breast cancer.

References

1. Grimm, S.W., and Dyroff, M.C. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. *Drug Metab. Disp.* **25(5)**, 598-602 (1997).
2. Plourde, P.V., Dyroff, M.C., and Dukes, M. Arimidex®: A potent and selective fourth-generation aromatase inhibitor. *Breast Cancer Res. Treat.* **30(1)**, 103-111 (1994).
3. Kubatka, P., Sadlonová, V., Kajo, K., *et al.* Chemopreventive effects of anastrozole in a premenopausal breast cancer model. *Anticancer Res.* **28(5A)**, 2819-2823 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM